James Chen, RN, BSN, CCRC
See Publications

Texas Heart Institute Positions

Education

  • Undergraduate:

    Baylor University

Certifications

  • Association of Clinical Research Professionals

Publications

4862227 KXW8KUFU 1 alternatives-to-animal-experimentation 10 date desc Chen 1861 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22Z2KFACN7%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22ACTIV-3%5C%2FTICO%20Study%20Group%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BACTIV-3%5C%2FTICO%20Study%20Group%2C%20Rogers%2C%20A.%20J.%2C%20Wentworth%2C%20D.%20et%20al.%20%282022%29.%20The%20association%20of%20baseline%20plasma%20sars-cov-2%20nucleocapsid%20antigen%20level%20and%20outcomes%20in%20patients%20hospitalized%20with%20COVID-19.%20%26lt%3Bi%26gt%3BAnn%20Intern%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B175%26lt%3B%5C%2Fi%26gt%3B%2C%201401%26%23x2013%3B1410.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM22-0924%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM22-0924%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20association%20of%20baseline%20plasma%20sars-cov-2%20nucleocapsid%20antigen%20level%20and%20outcomes%20in%20patients%20hospitalized%20with%20COVID-19%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ACTIV-3%5C%2FTICO%20Study%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20J.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deborah%22%2C%22lastName%22%3A%22Wentworth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katy%22%2C%22lastName%22%3A%22Shaw-Saliba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%20L.%22%2C%22lastName%22%3A%22Dewar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%20R.%22%2C%22lastName%22%3A%22Aggarwal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdel%20G.%22%2C%22lastName%22%3A%22Babiker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Weizhong%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nila%20J.%22%2C%22lastName%22%3A%22Dharan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%20J.%22%2C%22lastName%22%3A%22Davey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20S.%22%2C%22lastName%22%3A%22Higgs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norman%22%2C%22lastName%22%3A%22Gerry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adit%20A.%22%2C%22lastName%22%3A%22Ginde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%20Awori%22%2C%22lastName%22%3A%22Hayanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Highbarger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeroen%20L.%22%2C%22lastName%22%3A%22Highbarger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mamta%20K.%22%2C%22lastName%22%3A%22Jain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginia%22%2C%22lastName%22%3A%22Kan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kami%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Lallemand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20G.%22%2C%22lastName%22%3A%22Leshnower%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20K.%22%2C%22lastName%22%3A%22Lutaakome%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gail%22%2C%22lastName%22%3A%22Matthews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Mourad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleftherios%22%2C%22lastName%22%3A%22Mylonakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ven%22%2C%22lastName%22%3A%22Natarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20L.%22%2C%22lastName%22%3A%22Padilla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lavannya%20M.%22%2C%22lastName%22%3A%22Pandit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Paredes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Pett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srikanth%22%2C%22lastName%22%3A%22Ramachandruni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20Tauseef%22%2C%22lastName%22%3A%22Rehman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brad%20T.%22%2C%22lastName%22%3A%22Sherman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20Clark%22%2C%22lastName%22%3A%22Files%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20M.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Matthay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20Taylor%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20D.%22%2C%22lastName%22%3A%22Neaton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Clifford%22%2C%22lastName%22%3A%22Lane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%20D.%22%2C%22lastName%22%3A%22Lundgren%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Levels%20of%20plasma%20SARS-CoV-2%20nucleocapsid%20%28N%29%20antigen%20may%20be%20an%20important%20biomarker%20in%20patients%20with%20COVID-19%20and%20enhance%20our%20understanding%20of%20the%20pathogenesis%20of%20COVID-19.%5CnOBJECTIVE%3A%20To%20evaluate%20whether%20levels%20of%20plasma%20antigen%20can%20predict%20short-term%20clinical%20outcomes%20and%20identify%20clinical%20and%20viral%20factors%20associated%20with%20plasma%20antigen%20levels%20in%20hospitalized%20patients%20with%20SARS-CoV-2.%5CnDESIGN%3A%20Cross-sectional%20study%20of%20baseline%20plasma%20antigen%20level%20from%202540%20participants%20enrolled%20in%20the%20TICO%20%28Therapeutics%20for%20Inpatients%20With%20COVID-19%29%20platform%20trial%20from%20August%202020%20to%20November%202021%2C%20with%20additional%20data%20on%20day%205%20outcome%20and%20time%20to%20discharge.%5CnSETTING%3A%20114%20centers%20in%2010%20countries.%5CnPARTICIPANTS%3A%20Adults%20hospitalized%20for%20acute%20SARS-CoV-2%20infection%20with%2012%20days%20or%20less%20of%20symptoms.%5CnMEASUREMENTS%3A%20Baseline%20plasma%20viral%20N%20antigen%20level%20was%20measured%20at%20a%20central%20laboratory.%20Delta%20variant%20status%20was%20determined%20from%20baseline%20nasal%20swabs%20using%20reverse%20transcriptase%20polymerase%20chain%20reaction.%20Associations%20between%20baseline%20patient%20characteristics%20and%20viral%20factors%20and%20baseline%20plasma%20antigen%20levels%20were%20assessed%20using%20both%20unadjusted%20and%20multivariable%20modeling.%20Association%20between%20elevated%20baseline%20antigen%20level%20of%201000%20ng%5C%2FL%20or%20greater%20and%20outcomes%2C%20including%20worsening%20of%20ordinal%20pulmonary%20scale%20at%20day%205%20and%20time%20to%20hospital%20discharge%2C%20were%20evaluated%20using%20logistic%20regression%20and%20Fine-Gray%20regression%20models%2C%20respectively.%5CnRESULTS%3A%20Plasma%20antigen%20was%20below%20the%20level%20of%20quantification%20in%205%25%20of%20participants%20at%20enrollment%2C%20and%201000%20ng%5C%2FL%20or%20greater%20in%2057%25.%20Baseline%20pulmonary%20severity%20of%20illness%20was%20strongly%20associated%20with%20plasma%20antigen%20level%2C%20with%20mean%20plasma%20antigen%20level%203.10-fold%20higher%20among%20those%20requiring%20noninvasive%20ventilation%20or%20high-flow%20nasal%20cannula%20compared%20with%20room%20air%20%2895%25%20CI%2C%202.22%20to%204.34%29.%20Plasma%20antigen%20level%20was%20higher%20in%20those%20who%20lacked%20antispike%20antibodies%20%286.42%20fold%3B%20CI%2C%205.37%20to%207.66%29%20and%20in%20those%20with%20the%20Delta%20variant%20%281.73%20fold%3B%20CI%2C%201.41%20to%202.13%29.%20Additional%20factors%20associated%20with%20higher%20baseline%20antigen%20level%20included%20male%20sex%2C%20shorter%20time%20since%20hospital%20admission%2C%20decreased%20days%20of%20remdesivir%2C%20and%20renal%20impairment.%20In%20contrast%2C%20race%2C%20ethnicity%2C%20body%20mass%20index%2C%20and%20immunocompromising%20conditions%20were%20not%20associated%20with%20plasma%20antigen%20levels.%20Plasma%20antigen%20level%20of%201000%20ng%5C%2FL%20or%20greater%20was%20associated%20with%20a%20markedly%20higher%20odds%20of%20worsened%20pulmonary%20status%20at%20day%205%20%28odds%20ratio%2C%205.06%20%5BCI%2C%203.41%20to%207.50%5D%29%20and%20longer%20time%20to%20hospital%20discharge%20%28median%2C%207%20vs.%204%20days%3B%20subhazard%20ratio%2C%200.51%20%5BCI%2C%200.45%20to%200.57%5D%29%2C%20with%20subhazard%20ratios%20similar%20across%20all%20levels%20of%20baseline%20pulmonary%20severity.%5CnLIMITATIONS%3A%20Plasma%20samples%20were%20drawn%20at%20enrollment%2C%20not%20hospital%20presentation.%20No%20point-of-care%20test%20to%20measure%20plasma%20antigen%20is%20currently%20available.%5CnCONCLUSION%3A%20Elevated%20plasma%20antigen%20is%20highly%20associated%20with%20both%20severity%20of%20pulmonary%20illness%20and%20clinically%20important%20patient%20outcomes.%20Multiple%20clinical%20and%20viral%20factors%20are%20associated%20with%20plasma%20antigen%20level%20at%20presentation.%20These%20data%20support%20a%20potential%20role%20of%20ongoing%20viral%20replication%20in%20the%20pathogenesis%20of%20SARS-CoV-2%20in%20hospitalized%20patients.%5CnPRIMARY%20FUNDING%20SOURCE%3A%20U.S.%20government%20Operation%20Warp%20Speed%20and%20National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7326%5C%2FM22-0924%22%2C%22ISSN%22%3A%221539-3704%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228HHBIBI6%22%2C%22849YWXRD%22%2C%22B2JSS4XR%22%2C%22QSVIJDTT%22%2C%22KXW8KUFU%22%2C%22QU9YAHAV%22%2C%22ZEQKP47S%22%2C%22F4SX9Z9X%22%2C%22FA6KSIY7%22%2C%22BULWH4DD%22%2C%22GVTR6QC3%22%5D%2C%22dateModified%22%3A%222023-02-14T20%3A20%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22KKUBYQ2D%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perin%20et%20al.%22%2C%22parsedDate%22%3A%222012-04-25%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPerin%2C%20E.%20C.%2C%20Willerson%2C%20J.%20T.%2C%20Pepine%2C%20C.%20J.%20et%20al.%20%282012%29.%20Effect%20of%20transendocardial%20delivery%20of%20autologous%20bone%20marrow%20mononuclear%20cells%20on%20functional%20capacity%2C%20left%20ventricular%20function%2C%20and%20perfusion%20in%20chronic%20heart%20failure%3A%20the%20FOCUS-CCTRN%20trial.%20%26lt%3Bi%26gt%3BJAMA%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B307%26lt%3B%5C%2Fi%26gt%3B%2C%201717%26%23x2013%3B1726.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjama.2012.418%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjama.2012.418%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20transendocardial%20delivery%20of%20autologous%20bone%20marrow%20mononuclear%20cells%20on%20functional%20capacity%2C%20left%20ventricular%20function%2C%20and%20perfusion%20in%20chronic%20heart%20failure%3A%20the%20FOCUS-CCTRN%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emerson%20C.%22%2C%22lastName%22%3A%22Perin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carl%20J.%22%2C%22lastName%22%3A%22Pepine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20D.%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20G.%22%2C%22lastName%22%3A%22Ellis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20X.%20M.%22%2C%22lastName%22%3A%22Zhao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilherme%20V.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dejian%22%2C%22lastName%22%3A%22Lai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20D.%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marvin%20W.%22%2C%22lastName%22%3A%22Kronenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20Daniel%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20David%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%20H.%22%2C%22lastName%22%3A%22Traverse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20S.%22%2C%22lastName%22%3A%22Penn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saif%22%2C%22lastName%22%3A%22Anwaruddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonis%20K.%22%2C%22lastName%22%3A%22Hatzopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrian%20P.%22%2C%22lastName%22%3A%22Gee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doris%20A.%22%2C%22lastName%22%3A%22Taylor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20R.%22%2C%22lastName%22%3A%22Cogle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deirdre%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lynette%22%2C%22lastName%22%3A%22Westbrook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eileen%22%2C%22lastName%22%3A%22Handberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20E.%22%2C%22lastName%22%3A%22Olson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carrie%22%2C%22lastName%22%3A%22Geither%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sherry%22%2C%22lastName%22%3A%22Bowman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judy%22%2C%22lastName%22%3A%22Francescon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Baraniuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%20B.%22%2C%22lastName%22%3A%22Piller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20M.%22%2C%22lastName%22%3A%22Simpson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catalin%22%2C%22lastName%22%3A%22Loghin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Aguilar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Richman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Zierold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judy%22%2C%22lastName%22%3A%22Bettencourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shelly%20L.%22%2C%22lastName%22%3A%22Sayre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20W.%22%2C%22lastName%22%3A%22Vojvodic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%20I.%22%2C%22lastName%22%3A%22Skarlatos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Gordon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ray%20F.%22%2C%22lastName%22%3A%22Ebert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minjung%22%2C%22lastName%22%3A%22Kwak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lemuel%20A.%22%2C%22lastName%22%3A%22Moy%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20D.%22%2C%22lastName%22%3A%22Simari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Cardiovascular%20Cell%20Therapy%20Research%20Network%20%28CCTRN%29%22%7D%5D%2C%22abstractNote%22%3A%22CONTEXT%3A%20Previous%20studies%20using%20autologous%20bone%20marrow%20mononuclear%20cells%20%28BMCs%29%20in%20patients%20with%20ischemic%20cardiomyopathy%20have%20demonstrated%20safety%20and%20suggested%20efficacy.%5CnOBJECTIVE%3A%20To%20determine%20if%20administration%20of%20BMCs%20through%20transendocardial%20injections%20improves%20myocardial%20perfusion%2C%20reduces%20left%20ventricular%20end-systolic%20volume%20%28LVESV%29%2C%20or%20enhances%20maximal%20oxygen%20consumption%20in%20patients%20with%20coronary%20artery%20disease%20or%20LV%20dysfunction%2C%20and%20limiting%20heart%20failure%20or%20angina.%5CnDESIGN%2C%20SETTING%2C%20AND%20PATIENTS%3A%20A%20phase%202%20randomized%20double-blind%2C%20placebo-controlled%20trial%20of%20symptomatic%20patients%20%28New%20York%20Heart%20Association%20classification%20II-III%20or%20Canadian%20Cardiovascular%20Society%20classification%20II-IV%29%20with%20a%20left%20ventricular%20ejection%20fraction%20of%2045%25%20or%20less%2C%20a%20perfusion%20defect%20by%20single-photon%20emission%20tomography%20%28SPECT%29%2C%20and%20coronary%20artery%20disease%20not%20amenable%20to%20revascularization%20who%20were%20receiving%20maximal%20medical%20therapy%20at%205%20National%20Heart%2C%20Lung%2C%20and%20Blood%20Institute-sponsored%20Cardiovascular%20Cell%20Therapy%20Research%20Network%20%28CCTRN%29%20sites%20between%20April%2029%2C%202009%2C%20and%20April%2018%2C%202011.%5CnINTERVENTION%3A%20Bone%20marrow%20aspiration%20%28isolation%20of%20BMCs%20using%20a%20standardized%20automated%20system%20performed%20locally%29%20and%20transendocardial%20injection%20of%20100%20million%20BMCs%20or%20placebo%20%28ratio%20of%202%20for%20BMC%20group%20to%201%20for%20placebo%20group%29.%5CnMAIN%20OUTCOME%20MEASURES%3A%20Co-primary%20end%20points%20assessed%20at%206%20months%3A%20changes%20in%20LVESV%20assessed%20by%20echocardiography%2C%20maximal%20oxygen%20consumption%2C%20and%20reversibility%20on%20SPECT.%20Phenotypic%20and%20functional%20analyses%20of%20the%20cell%20product%20were%20performed%20by%20the%20CCTRN%20biorepository%20core%20laboratory.%5CnRESULTS%3A%20Of%20153%20patients%20who%20provided%20consent%2C%20a%20total%20of%2092%20%2882%20men%3B%20average%20age%3A%2063%20years%29%20were%20randomized%20%28n%20%3D%2061%20in%20BMC%20group%20and%20n%20%3D%2031%20in%20placebo%20group%29.%20Changes%20in%20LVESV%20index%20%28-0.9%20mL%5C%2Fm%282%29%20%5B95%25%20CI%2C%20-6.1%20to%204.3%5D%3B%20P%20%3D%20.73%29%2C%20maximal%20oxygen%20consumption%20%281.0%20%5B95%25%20CI%2C%20-0.42%20to%202.34%5D%3B%20P%20%3D%20.17%29%2C%20and%20reversible%20defect%20%28-1.2%20%5B95%25%20CI%2C%20-12.50%20to%2010.12%5D%3B%20P%20%3D%20.84%29%20were%20not%20statistically%20significant.%20There%20were%20no%20differences%20found%20in%20any%20of%20the%20secondary%20outcomes%2C%20including%20percent%20myocardial%20defect%2C%20total%20defect%20size%2C%20fixed%20defect%20size%2C%20regional%20wall%20motion%2C%20and%20clinical%20improvement.%5CnCONCLUSION%3A%20Among%20patients%20with%20chronic%20ischemic%20heart%20failure%2C%20transendocardial%20injection%20of%20autologous%20BMCs%20compared%20with%20placebo%20did%20not%20improve%20LVESV%2C%20maximal%20oxygen%20consumption%2C%20or%20reversibility%20on%20SPECT.%5CnTRIAL%20REGISTRATION%3A%20clinicaltrials.gov%20Identifier%3A%20NCT00824005.%22%2C%22date%22%3A%22Apr%2025%2C%202012%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjama.2012.418%22%2C%22ISSN%22%3A%221538-3598%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%22LPUKMNGT%22%2C%228HHBIBI6%22%2C%222K4N54U2%22%2C%22KXW8KUFU%22%2C%228PULYTSK%22%5D%2C%22dateModified%22%3A%222018-05-02T20%3A35%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22D94WIHJV%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Beal%20et%20al.%22%2C%22parsedDate%22%3A%222004-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBeal%2C%20K.%2C%20Dean%2C%20J.%2C%20%26lt%3Bstrong%26gt%3BChen%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20et%20al.%20%282004%29.%20Budget%20negotiation%20for%20industry-sponsored%20clinical%20trials.%20%26lt%3Bi%26gt%3BAnesth%20Analg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B99%26lt%3B%5C%2Fi%26gt%3B%2C%20173%26%23x2013%3B176%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Budget%20negotiation%20for%20industry-sponsored%20clinical%20trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristy%22%2C%22lastName%22%3A%22Beal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Dean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Dragaon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%22%2C%22lastName%22%3A%22Saulino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20D.%22%2C%22lastName%22%3A%22Collard%22%7D%5D%2C%22abstractNote%22%3A%22The%20specialty%20of%20anesthesia%20is%20well%20suited%20to%20attract%20industry-sponsored%20clinical%20trials%20and%20research%20revenues%20because%20of%20its%20fundamental%20contributions%20to%20surgery%2C%20critical%20care%2C%20and%20pain%20medicine.%20However%2C%20the%20performance%20and%20budgeting%20of%20industry-sponsored%20clinical%20research%20over%20the%20past%20decade%20has%20been%20significantly%20altered%20by%20the%20rapid%20growth%20of%20commercially%20oriented%20networks%20of%20contract-research%20organizations%20and%20site-management%20organizations.%20Further%2C%20the%20competitive%20nature%20of%20today%26%23039%3Bs%20clinical%20research%20climate%20can%20make%20the%20planning%20and%20negotiating%20of%20study%20budgets%20and%20contracts%20stressful%2C%20time%20consuming%2C%20frustrating%2C%20and%20full%20of%20pitfalls.%20Because%20a%20clinical%20trial%20contract%20is%20a%20fixed-price%20agreement%2C%20investigators%20are%20obligated%20to%20perform%20the%20work%20described%20in%20the%20contract%2C%20even%20if%20the%20actual%20costs%20exceed%20the%20study%20contract.%20Successful%20budgeting%20for%20the%20performance%20of%20an%20industry-sponsored%20clinical%20trial%20thus%20requires%20a%20thorough%20understanding%20of%20the%20direct%20and%20indirect%20costs%20associated%20with%20performing%20clinical%20research.%20We%20reviewed%20budget%20and%20contractual%20considerations%20for%20the%20successful%20negotiation%20and%20performance%20of%20industry-sponsored%20clinical%20research.%22%2C%22date%22%3A%22Jul%202004%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220003-2999%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22R4DG8MRF%22%2C%22KXW8KUFU%22%5D%2C%22dateModified%22%3A%222018-05-23T19%3A25%3A56Z%22%7D%7D%5D%7D
ACTIV-3/TICO Study Group, Rogers, A. J., Wentworth, D. et al. (2022). The association of baseline plasma sars-cov-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19. Ann Intern Med 175, 1401–1410. https://doi.org/10.7326/M22-0924.
Perin, E. C., Willerson, J. T., Pepine, C. J. et al. (2012). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 307, 1717–1726. https://doi.org/10.1001/jama.2012.418.
Beal, K., Dean, J., Chen, J. et al. (2004). Budget negotiation for industry-sponsored clinical trials. Anesth Analg 99, 173–176

The Texas Heart Institute® at Baylor College of Medicine 2025

Privacy Policy & Terms of Use

Bringing the future of cardiovascular health to life.®